Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation transactions should be finished after this ..

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 06, 2021 6:53pm

192 Views

Post# 33338050

RE:RE:RE:Amalgamation transactions should be finished after this ..

Doccole wrote:
I assumed there was selling from insiders. The Canadian volume was high...

Insider selling tells me there is nothing on the horizon, or why would insider sell? Am I wrong? Please tell me I am?!

Doccole ... tell me if I'm wrong ...

I think we're talking about Dan's sale of $300K in shares and his acquisition of $2,500,000 in shares.

So Dan's buying a used Lambo and McNeece is getting into a Tesla.

: )

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing